4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL

CONFERENCE AGENDA

Registrations	08:00 - 08:50
Welcome address by MarketsandMarkets	08:50 - 08:55
Opening remarks by Chairperson Petter Bjorquist, CEO, Verigraft	08:55 - 09:00
Personalised organs that will revolutionise future medicine Petter Bjorquist, CEO, Verigraft	09:00 - 09:30
UPSTREAM PROCESSING OF CELL & GENE THERAPIES
Bioprocessing of cells and exosomes for regenerative medicine Ivan Wall, Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing, Aston University	09:25 - 09:50
Automated Cell Culture Analysis – Process Development to GMP Roystein Bulman, European Applications Manager, Nova Biomedical	09:50 - 10:20
Development of Combinatorial Culture Technology for cell and gene therapy applications Marina Tarunina, Research Director, Plasticell Limited	10:20 - 10:45
Authentic human cytokines and growth factors for ATMPs from process development through GMP Fiona Bellot, Protein Sales Manager, Proteintech	10:45 - 11:00
The application of light scattering to viral vector analysis; Applications for research, QC and in-line process control Kevin Jackson, Technical Director, Wyatt Technology, UK	11:00 - 11:15
The potential of NKG2D CAR T cells as a therapy for cancer David Gilham, Vice President Research & Development, Celyad	11:15 - 11:50
Cell therapy development for solid tumors - Brought to the next Level by Image Cytometry Martin Theiss, Senior Field Application Scientist, Nexcelom Bioscience	11:50 - 12:20
Networking break	12:20 - 12:20
DOWNSTREAM PROCESSING OF CELL & GENE THERAPIES
An innovative strategy for the production of clinical grade induced pluripotent stem cells Victoria Robertson, Quality Control Manager, RoslinCT, UK	12:40 - 12:55
Pragmatic drug development solutions for virtual and semi-virtual sponsors Nick Meyers, VP Product Development, Boyd Consultants Ltd	12:55 - 13:10
Enabling Autologous CAR T manufacturing at point of care Ohad Karneili, Founder & CEO, Adva Biotechnology	13:10 - 13:35
Closing remarks	13:35 - 13:40
Networking break	13:40 - 14:10
End of Day 1	14:10 - 14:10

Registrations	08:15 - 08:50
Welcome address by MarketsandMarkets	08:50 - 08:55
Opening remarks by Chairperson	08:55 - 09:00
ANALYTICS AND QUALITY CONTROL FOR CELL AND GENE THERAPY PRODUCTS
Starting materials and standards for stem cell-based therapies Elsa Abranches, Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank	09:00 - 09:30
Engineering characterisation of DASGIP bioreactors towards the optimisation of iPSC-derived Cardiomyocyte differentiation process Andrea Ducci, Associate Professor, UCL Mechanical Engineering	09:25 - 09:50
Analysis of process related impurities in cell & gene therapy products by LC-MS Ejvind Mortz, Chief Operating Officer, Alphalyse	09:50 - 10:20
Extending the shelf life of cell therapy products: No need to freeze Steve Swioklo, CSO and Co-founder, Atelerix Ltd	10:20 - 10:50
To go Viral, or to go Non-Viral, that is the question for cell modification Stefano Baila, Director of Operations & Business Development, Anemocyte	10:50 - 11:15
Networking Break	11:15 - 11:30
Data management and data science tools for accelerating time to market Christoph Herwig, Bioprocess development & facility design, Werum IT Solutions	11:30 - 12:00
LOGISTICS, REGULATORY & INVESTMENT
Raw and starting material control for cell-based medicines Christiane Niederlaender, Regulatory Consultant and Director, AMBR Consulting	12:00 - 12:30
Delving deeper into AAV attributes: Enhanced characterization using multiple technologies John Stenson, Product Manager, Nanomaterials, Malvern Panalytical	12:25 - 12:40
Public sector development of cell and gene therapies Tristan Pritchard-Meaker, , Leiden University Medical Centre	12:40 - 13:05
Unlocking value and investment opportunities in the cell-gene therapy industry	13:05 - 13:30
Closing remarks by Chairperson	13:30 - 13:35
End of Conference	13:35 - 13:35